TY - JOUR
T1 - Three decades of nucleic acid aptamer technologies
T2 - Lessons learned, progress and opportunities on aptamer development
AU - Wang, Tao
AU - Chen, Changying
AU - Larcher, Leon M.
AU - Barrero, Roberto A.
AU - Veedu, Rakesh N.
N1 - Funding Information:
R.N.V. greatly acknowledges financial support from the Department of Health (Merit Award) the Western Australian Government, Australia; the McCusker Charitable Foundation; and the Perron Institute for Neurological and Translational Science. T.W is supported by Murdoch University commercial research funding. T.W and C.Y.C acknowledges the funding from the National Natural Science Foundation of China (No. 81773175 and No.11704343) and the China Postdoctoral Science Foundation (No. 2018M630839). The authors thank Yuhan Wang and Tamer R. Kosbar for help towards fig. preparation and Hadi A. Shamaileh for informative discussion.
Funding Information:
R.N.V. greatly acknowledges financial support from the Department of Health (Merit Award) the Western Australian Government , Australia; the McCusker Charitable Foundation ; and the Perron Institute for Neurological and Translational Science . T.W is supported by Murdoch University commercial research funding. T.W and C.Y.C acknowledges the funding from the National Natural Science Foundation of China (No. 81773175 and No. 11704343 ) and the China Postdoctoral Science Foundation (No. 2018M630839 ). The authors thank Yuhan Wang and Tamer R. Kosbar for help towards fig. preparation and Hadi A. Shamaileh for informative discussion.
Publisher Copyright:
© 2018 The Authors
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Aptamers are short single-stranded nucleic acid sequences capable of binding to target molecules in a way similar to antibodies. Due to various advantages such as prolonged shelf life, low batch to batch variation, low/no immunogenicity, freedom to incorporate chemical modification for enhanced stability and targeting capacity, aptamers quickly found their potential in diverse applications ranging from therapy, drug delivery, diagnosis, and functional genomics to bio-sensing. Aptamers are generated by a process called SELEX. However, the current overall success rate of SELEX is far from being satisfactory, and still presents a major obstacle for aptamer-based research and application. The need for an efficient selection strategy consisting of defined procedures to deal with a wide variety of targets is significantly important. In this work, by analyzing key aspects of SELEX including initial library design, target preparation, PCR optimization, and single strand DNA separation, we provide a comprehensive analysis of individual steps to facilitate researchers intending to develop personalized protocols to address many of the obstacles in SELEX. In addition, this review provides suggestions and opinions for future aptamer development procedures to address the concerns on key SELEX steps, and post-SELEX modifications.
AB - Aptamers are short single-stranded nucleic acid sequences capable of binding to target molecules in a way similar to antibodies. Due to various advantages such as prolonged shelf life, low batch to batch variation, low/no immunogenicity, freedom to incorporate chemical modification for enhanced stability and targeting capacity, aptamers quickly found their potential in diverse applications ranging from therapy, drug delivery, diagnosis, and functional genomics to bio-sensing. Aptamers are generated by a process called SELEX. However, the current overall success rate of SELEX is far from being satisfactory, and still presents a major obstacle for aptamer-based research and application. The need for an efficient selection strategy consisting of defined procedures to deal with a wide variety of targets is significantly important. In this work, by analyzing key aspects of SELEX including initial library design, target preparation, PCR optimization, and single strand DNA separation, we provide a comprehensive analysis of individual steps to facilitate researchers intending to develop personalized protocols to address many of the obstacles in SELEX. In addition, this review provides suggestions and opinions for future aptamer development procedures to address the concerns on key SELEX steps, and post-SELEX modifications.
KW - Aptamer
KW - PCR bias
KW - SELEX
KW - SELEX library
KW - Single-strand DNA preparation
KW - Synthetic genetic polymers
UR - http://www.scopus.com/inward/record.url?scp=85056241824&partnerID=8YFLogxK
U2 - 10.1016/j.biotechadv.2018.11.001
DO - 10.1016/j.biotechadv.2018.11.001
M3 - Review article
SN - 0734-9750
VL - 37
SP - 28
EP - 50
JO - Biotechnology Advances
JF - Biotechnology Advances
IS - 1
ER -